በሞንታና ለየጡንቻ ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች
ለየጡንቻ ካንሰር የሚደረጉ 13 ጥናቶች በሞንታና ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በሞንታና ውስጥ ያሉ ከተሞች
Official study text (English)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Intermountain Healthcare, Billings
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- እና 7 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07007559Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT06797635A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute), Billings
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 55 · ሴቶች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT07310420Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
- እና 10 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 60 · ሴቶች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT05879926Integrated Cancer Repository for Cancer Research
- Bozeman Health Deaconess Hospital, Bozeman
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ19 እስከ 110 · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁን 2026 · NCT02012699Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- SCL Health - Cancer Centers of Montana, Billings
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሜይ 2026 · NCT06757634De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- Benefis Sletten Cancer Institute, Great Falls
- እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ50 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ23 ኤፕሪ 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
- እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06418204Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
- University of Montana, Missoula
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 89 · ሁሉም ጾታዎች · የተሻሻለው በ5 ፌብሩ 2026 · NCT07001241SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Billings
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Benefis Healthcare- Sletten Cancer Institute, Great Falls
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ኦክቶ 2025 · NCT03418961ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።